Zealand Pharma stock
Price history
−52.97% over the period1 year: from kr 524.40 (November 17, 2025) to kr 246.60 (November 16, 2026), −52.97%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | kr 246.60 |
| October 30, 2026 | kr 234.10 |
| September 30, 2026 | kr 271.10 |
| August 31, 2026 | kr 300.00 |
| July 31, 2026 | kr 304.00 |
| June 30, 2026 | kr 289.60 |
| May 29, 2026 | kr 324.90 |
| April 30, 2026 | kr 299.40 |
| March 31, 2026 | kr 295.00 |
| February 27, 2026 | kr 363.80 |
| January 30, 2026 | kr 420.10 |
| December 30, 2025 | kr 466.40 |
| November 28, 2025 | kr 516.40 |
| November 17, 2025 | kr 524.40 |
At a glance
The company
Biotechnology company developing peptide-based medicines for gastrointestinal and metabolic diseases, including Zegalogue for severe hypoglycemia treatment
Latest results
Quarter to September 30, 2026 · EPS -kr 10.02 (estimate -kr 9.63)
TickerLandia's take on Zealand Pharma
- Cheaper than similar companies: trailing 12-month P/E 5.5 vs 17 (−68%) in a group of 9.
- Strong point: Profitability (85/100 in its group). Weak point: Market momentum (3/100).
- “Beaten down but solid” (Denmark): No. 1 of 1.
- “Most upside for analysts” (Denmark): No. 1 of 21.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−55.65% from the 52-week high
Analysts · 16 analysts
Average targetkr 386.08+56.56% vs. price
Buy 6 · Hold 9 · Sell 1 · Buy
TickerLandia Fingerprint: Zealand Pharma
Compared with similar companies: very weak momentum, very high risk, and very high profitability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery low20
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 3.55 15 P/E (trailing 12 months) 5.57 9 Forward P/E 35.5 70 EV/EBITDA 1.13 1 Price/book 0.95 3 Profitabilityvery high85
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 59.0% 94 Net margin 67.2% 93 ROE 19.1% 67 Gross marginabove 100%: likely one-off items 100.0% 99 ROA 9.4% 73 Earnings stabilitylow24
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 813.5% 18 Loss-making yearscounts in reverse: lower means more earnings stability 4 of 5 annual reports 30 Growthaverage43
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +345.83% 94 Revenue growth (year over year) −92.00% 3 Earnings growth (year over year) −47.60% 32 Financial strengthhigh78
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.60 62 Interest coverage 238.0 84 Debt/equitycounts in reverse: lower means more financial strength 0.03 74 Current ratio 10.5 91 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak3
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −53.53% 1 Distance from 200-day average −19.75% 6 Riskvery high88
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 59.4% 98 Volatility (60 days) 37.4% 79
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Zealand Pharma is cheaper than similar companies
Zealand Pharma's P/E (trailing 12 months): 5.49, −68% against the median of a group of 9 similar companies (17.1).
Compared with 9 similar companies
| Metric | Zealand Pharma | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 5.49 | Low | |
| Forward P/E | 33.4 | Middle | |
| Operating margin | 59.0% | High | |
| ROE | 19.1% | Middle | |
| Debt/equity | 0.03 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Zealand Pharma. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 4.49B
Latest quarter · Q2 2026
Net income
kr 3.92B
Latest quarter · Q2 2026
Quarterly net margin
87.2%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- kr 16.05B
- P/E
- 5.5
- EPS
- kr 44.12
- Volume
- 388.91K
- Daily trading
- €11.4M
- Dividend yield
- 0.00%
How Zealand Pharma is changing
All resultsRevenue grew 116.9% a year on average over the last 5 years
Operating margin rose from −785.3% to 75.1%
Profits turn into cash: free cash flow equal to 110% of net income
Returns
Zealand Pharma returns
kr 1,000 invested in Zealand Pharma 5 years ago, on November 16, 2021, would be worth kr 1,561 today: +56.08% in total, +9.31% per year. This is the price return only: dividends are excluded.
| Period | Zealand Pharma | kr 1,000 becomes |
|---|---|---|
| 1 month | +8.97% | kr 1,090 |
| 6 months | −20.61% | kr 794 |
| Year to date | −47.13% | kr 529 |
| 1 year | −52.97% | kr 470 |
| 3 years | −19.25% | kr 807 |
| 5 years | +56.08% | kr 1,561 |
| 10 years | +122.16% | kr 2,222 |
Price only, without dividends. Calculate your investment
The chart in detail
Zealand Pharma: technical analysis
Zealand Pharma is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 74.2% below its all-time closing high (kr 954.00, July 10, 2024).
- Trend
- Downward
- RSI (14 sessions)
- 54
- Between 30 and 70
- vs 200-session average
- −18.00%
Support and resistance
Price areas where Zealand Pharma has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 306.28+24.20%6 touches, last on August 18, 2026
- Resistancekr 294.93+19.60%4 touches, last on September 18, 2026
- Resistancekr 272.05+10.32%4 touches, last on September 16, 2026
- Last pricekr 246.60
- Supportkr 235.50−4.50%2 touches, last on June 8, 2026
- Supportkr 220.85−10.44%2 touches, last on October 27, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 37.0%
- Largest fall in the last year
- −59.36%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Zealand Pharma: seasonality
Average monthly price change over 16 years
Over the last 16 years, the strongest month for Zealand Pharma has been July: +7.23% on average, positive in 11 years out of 16. The weakest has been August: −2.07% on average, positive in 6 years out of 16. November, the current month, has been positive in 7 years out of 15 (−1.68% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +5.14% | +4.78% | 11 of 16 |
| February | −1.15% | −2.40% | 5 of 16 |
| March | +2.11% | +2.45% | 9 of 16 |
| April | +0.12% | +0.41% | 9 of 16 |
| May | +1.85% | +0.59% | 9 of 16 |
| June | −1.04% | −3.56% | 7 of 16 |
| July | +7.23% | +4.59% | 11 of 16 |
| August | −2.07% | −2.06% | 6 of 16 |
| September | +4.22% | +1.81% | 9 of 16 |
| October | +0.32% | +0.38% | 8 of 16 |
| November | −1.68% | −0.66% | 7 of 15 |
| December | +0.55% | −0.99% | 6 of 16 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Zealand Pharma and its competitors
Patients with gastrointestinal and metabolic conditions, as well as those with other specialty diseases where treatment options remain limited, are the people the company's medicines are designed for. Zealand Pharma works across Denmark and the US, where it researches, develops and commercializes medicines built on peptides. Its product Zegalogue, a single-dose device for severe low blood sugar, sits alongside dasiglucagon-based systems for artificial pancreas use that combine insulin and dasiglucagon.
- Headquarters
- Søborg, Denmark
- Employees
- 605
- Founded
- 1997
- Chief executive
- Adam Steensberg
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Zealand PharmaZEAL | $2.37B | 59.0% | 5.49 | −20.61% |
| Bavarian NordicBAVA | $2.62B | 18.1% | 12.2 | +26.18% |
| Lakefront BiotherapeuticsLKFT | $2.2B | 57.5% | 3.21 | +33.42% |
| BioArcticBIOA.B | $2.74B | 19.6% | 262.7 | −3.82% |
| CamurusCAMX | $4.41B | 37.4% | 58.9 | +46.61% |
| Pharma MarPHM | $1.28B | 21.3% | 17.1 | −29.91% |
Same industry or related industries, similar size. Compare Zealand Pharma with its competitors · Full profile
